World-class Biology

for simplifying complex breast cancer decisions.


Now there is a single suite of assays based on the analysis of hundreds of genes in your patients’ breast cancer. The result is an unprecedented amount of biological information to help you address complex treatment decisions.

Breast Cancer Study
More than 500 tumors
were analyzed and followed
for a 10-year period in
women who received no
hormonal or chemotherapy.
Analysis of Entire
Human Genome

All 25,000 genes were
analyzed in each of the
500 breast tumors to
learn which genes were
differentially expressed.
Prognostic and Predictive
Researchers discovered which of the
25,000 genes were the best predictors for
determining the recurrence of breast cancer.
These predictive genes were also shown
to identify the women most likely to benefit
from the addition of chemotherapy.

 

Interpreting the Unique
SYMPHONY Biomarkers
Each of the following assays
provides vital information that
will help you make more informed
decisions for your patients:
  SYMPHONY Mammaprint
Blueprint
Targetprint
Theraprint